Rizatriptan Benzoate
Product Images NDC 71335-0810

5 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71335-0810). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713350810)

Label Image (Lbl713350810)
Label for Rizatriptan Benzoate 5 mg tablet blister pack by Bryant Ranch Prepack. The label compares it to Maxalt 5 mg tablet from InvaGen Pharmaceuticals. Contains 30 tablets with storage instructions and a barcode. NDC 71335-0810 is highlighted.*
FDA Label Image

Rizatriptan 01

Rizatriptan 01
Chemical structure of Rizatriptan Benzoate showing the molecular arrangement of its active ingredients, including the triptan component and benzoate group.*
FDA Label Image

Rizatriptan 02

Rizatriptan 02
A line graph depicting the estimated probability of response over time (hours post-dose) for placebo, Rizatriptan Benzoate 5 mg tablets, and Rizatriptan Benzoate 10 mg tablets. The graph shows increasing response rates up to 2 hours after dosing, with higher doses of Rizatriptan Benzoate showing higher probabilities of response compared to placebo.*
FDA Label Image

Rizatriptan 03

Rizatriptan 03
A line chart showing the estimated probability of remediation or rescue over 24 hours post-dose for Rizatriptan Benzoate Tablets at 5 mg and 10 mg doses compared to placebo. The x-axis represents hours post-dose, and the y-axis shows the estimated probability percentage, illustrating the effect of the drug over time relative to placebo.*
FDA Label Image

Rizatriptan 04

Rizatriptan 04
A line graph comparing the percentage response over time between Rizatriptan Benzoate orally disintegrating tablets and placebo. The x-axis shows hours post-stage 2 dose from 0.5 to 2.0, and the y-axis shows percent response with 95% confidence intervals, ranging from 0 to 100 percent.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.